

55311

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

# SEARCH REQUEST FORM

Requestor's Name: D. Dawron Serial Number: 09/351,057  
Date: 11/19/01 Phone: 306-3227 Art Unit: 1614  
Mail box 2D01 Office: 2E05

## Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

... Please search the trademark, Fluo-GRP™

GRP → gastrin-releasing peptide. Applicant is trying to obtain product information on this trademark.

Thanks  
CDM

RECEIVED  
NOV 21 2001  
JACQUES (STIC)

P.O. 1129

## STAFF USE ONLY

1056-00

Date completed: 11-24  
Searcher: Point of Contact:  
Alex Waclawiw  
Terminal time: Technical Info. Specialist  
Elapsed time: CM1 12C14 Tel: 308-4491  
CPU time: \_\_\_\_\_  
Total time: \_\_\_\_\_  
Number of Searches: \_\_\_\_\_  
Number of Databases: \_\_\_\_\_

### Search Site

\_\_\_\_ STIC  
☒ CM-1  
\_\_\_\_ Pre-S

### Type of Search

\_\_\_\_ N.A. Sequence  
\_\_\_\_ A.A. Sequence  
\_\_\_\_ Structure  
\_\_\_\_ Bibliographic

### Vendors

\_\_\_\_ IG  
☒ STN 53  
☒ Dialog 9900  
\_\_\_\_ APS  
\_\_\_\_ Geninfo  
\_\_\_\_ SDC  
\_\_\_\_ DARC/Questel  
\_\_\_\_ Other

① 25

problem getting onto Dialog

Connecting via Winsock to Dialog

Logging in to Dialog

Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

\*\*\*\*\*

ENTER PASSWORD:

\*\*\*\*\*

Welcome to DIALOG

Dialog level 01.10.01D

Last logoff: 29nov01 10:57:41

Logon file001 29nov01 11:20:18

Address "ADDEPTA" is now in use for Modem Outdial delivery.

\*\*\*\*

\*\*\*\*\*

File 1:ERIC 1966-2001/Nov 02  
(c) format only 2001 The Dialog Corporation

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

Cost is in DialUnits

? b 410

29nov01 11:20:19 User035515 Session D458.1

\$0.31 0.089 DialUnits File1

\$0.31 Estimated cost File1

\$0.31 Estimated cost this search

\$0.31 Estimated total session cost 0.089 DialUnits

File 410:Chronolog(R) 1981-2001/Nov  
(c) 2001 The Dialog Corporation

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

? set hi ;set hi

HILIGHT set on as ''

HILIGHT set on as ''

? sf trademks

>>>SELECT FILES not supported.

? b tmks

29nov01 11:20:46 User035515 Session D458.2

\$0.00 0.129 DialUnits File410

\$0.00 Estimated cost File410

\$0.08 TELNET

\$0.08 Estimated cost this search

\$0.39 Estimated total session cost 0.217 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 126:TRADEMARKSCAN(R)-U.K. 2001/Oct B2

(c) 2001 Compu-Mark N.V.

\*File 126: For latest Trademark issue information, TYPE 9999999/23.

\*IMAGES available (note: for images for WIPO records, use file 671).

. File 127:TRADEMARKSCAN(R)-CANADA 2001/NOV 20

(c) 2001 Thomson & Thomson  
\*File 127: For latest update information, TYPE 9999999/23.  
File 226:TRADEMARKSCAN(R)-US FED OG011127/AP011109  
(c) 2001 Thomson & Thomson  
\*File 226: Preliminary Records through 11/13/01 \*See HELP NEWS 226  
for info on UD=19991026 and changes to AP=9999.  
File 227:TRADEMARKSCAN(R)- Community Tmks 2001/Sep B2  
(c) 2001 Compu-Mark N.V.  
\*File 227: For latest issue info, TYPE 9999999/23.  
\*Images available.  
File 228:TRADEMARKSCAN(R)-Spain 2001/Oct B1  
(c) 2001Compu-Mark N.V.  
\*File 228: For latest issue information, TYPE 9999999/23.  
IMAGES available (for WIPO records, use File 671).  
File 246:TRADEMARKSCAN(R)-U.S. STATE 2001/NOV 20  
(c) 2001 THOMSON & THOMSON  
\*File 246: For latest update information, TYPE 9999999/23.  
File 657:TRADEMARKSCAN(R)-France 2001/Oct B1  
(c) 2001 Compu-Mark N.V.  
\*File 657: For latest Trademark issue information, TYPE 9999999/23.  
\*IMAGES available (note: for images for WIPO records, use file 671).  
File 658:TRADEMARKSCAN(R)-Benelux 2001/Oct B2  
(c) 2001 Compu-Mark N.V.  
\*File 658: For latest Trademark issue information, TYPE 9999999/23.  
\*IMAGES available (note: for images for WIPO records, use file 671).  
File 659:TRADEMARKSCAN(R)-Denmark 2001/Oct B2  
(c) 2001 Compu-Mark N.V.  
\*File 659: For latest trademark issue information, TYPE 9999999/23.  
\*IMAGES available (note: for images for WIPO records, use file 671).  
File 661:TRADEMARKSCAN(R)-Switzerland 2001/Oct B1  
(c) 2001 Compu-Mark N.V.  
\*File 661: For latest Trademark issue information, TYPE 9999999/23.  
\*IMAGES available (for images for WIPO records, use file 671).  
File 662:TRADEMARKSCAN(R)-Austria 2001/Oct B1  
(c) 2001 Compu-Mark N.V.  
\*File 662: For latest Trademark issue information, TYPE 9999999/23.  
\*IMAGES available (for images for WIPO records, use file 671).  
File 663:TRADEMARKSCAN(R)-Monaco 2001/Oct B1  
(c) 2001 Compu-Mark N.V.  
\*File 663: For latest issue info, TYPE 9999999/23. Madrid Protocol marks  
\*included. IMAGES available (for images for WIPO records, use file 671).  
File 669:TRADEMARKSCAN(R)-Japan 2001/Nov  
(c) 2001 Thomson & Thomson  
File 671:TRADEMARKSCAN(R)-Intl Register 2001/Oct B1  
(c) 2001 Compu-Mark N.V.  
\*File 671: For latest issue info, TYPE 9999999/23.  
Madrid Protocol marks included. Images available.  
File 672:TRADEMARKSCAN(R)-Germany 2001/Oct B1  
(c) 2001 Compu-Mark N.V.  
\*File 672: For latest issue info, TYPE 9999999/23. Madrid Protocol marks  
\*included. IMAGES available (for images for WIPO records, use file 671)  
File 673:TRADEMARKSCAN(R)-Italy 2001/Oct B1  
(c) 2001 Compu-Mark N.V.  
\*File 673: For latest trademark issue information, TYPE 9999999/23.  
\*IMAGES available (note: for images for WIPO records, use file 671).  
File 677:TRADEMARKSCAN(R)-Liechtenstein 2001/Oct B1  
(c) 2001 Compu-Mark N.V.  
\*File 677: For latest Trademark issue information, TYPE 9999999/23

Set Items Description

```

--- -----
? s fluo()grp
      189 FLUO
      87 GRP
      S1 0 FLUO()GRP
? s flu? ? and grp
      1283 FLU? ?
      87 GRP
      S2 0 FLU? ? AND GRP
? s gastrin ()releasing ()peptide?
      5 GASTRIN
      40 RELEASING
      173 PEPTIDE?
      S3 0 GASTRIN ()RELEASING ()PEPTIDE?
? s gastrin
      S4 5 GASTRIN

? t 4/9/all

```

4/9/1 (Item 1 from file: 227)  
 DIALOG(R)File 227:TRADEMARKSCAN(R)- Community Tmks  
 (c) 2001 Compu-Mark N.V. All rts. reserv.

00065036

GASTRIN

INTL CLASS: 3 (Cosmetics and cleaning preparations)  
 5 (Pharmaceuticals)  
 30 (Staple foods)

STATUS: Published Application (Pending)

GOODS/SERVICES AS FILED:

<ITALIAN> 03 PREPARATI PER LA SBIANCA ED ALTRE SOSTANZE PER IL  
 BUCATO; PREPARATI PER PULIRE, LUCIDARE, SGRASSARE ED ABRADERE;  
 SAPONI; PROFUMERIA, OLI ESSENZIALI; COSMETICI, LOZIONI PER  
 CAPELLI; DENTIFRICI.

05 PRODOTTI FARMACEUTICI, INFUSIONI MEDICINALI, SOSTANZE  
 DIETETICHE PER USO MEDICO ED INTEGRATORI DIETETICI.

30 CAFFE, TE, CACAO, ZUCCHERO, RISO, TAPIOCA, SAGO, SUCCEDANEI  
 DEL CAFFE; FARINE E PREPARATI FATTI DI CEREALI, PANE, PASTICCERIA,  
 CONFETTERIA, GELATI; MIELE, SCIROPPO DI MELASSA; SALE; SENAPE;  
 ACETO; SPEZIE; GHIACCIO; GOMME DA MASTICARE, INTEGRATORI  
 ALIMENTARI.

<ENGLISH> 03 BLEACHING PREPARATIONS AND OTHER SUBSTANCES FOR  
 LAUNDRY USE; CLEANING, POLISHING, SCOURING AND ABRASIVE  
 PREPARATIONS; SOAPS; PERFUMERY, ESSENTIAL OILS; COSMETICS, HAIR  
 LOTIONS; DENTIFRICES.

05 PHARMACEUTICAL PREPARATIONS, MEDICINAL INFUSIONS, DIETETIC  
 SUBSTANCES ADAPTED FOR MEDICAL USE AND DIETETIC SUPPLEMENTS.

30 COFFEE, TEA, COCOA, SUGAR, RICE, TAPIOCA, SAGO, ARTIFICIAL  
 COFFEE; FLOUR AND PREPARATIONS MADE FROM CEREALS, BREAD, PASTRY  
 AND CONFECTIONERY, ICES; HONEY, TREACLE; SALT, MUSTARD; VINEGAR;  
 SPICES; ICE; CHEWING GUM, NUTRITIONAL SUPPLEMENTS.

LANGUAGES: ITALIAN (Language of the application); ENGLISH (Second  
 language)

APPLICATION NUMBER: 654293

APPLICATION DATE: 10 October 1997 (October 10, 1997)

RECEIVED AT OHIM: 10 October 1997 (October 10, 1997)

LAST FULL PUBLICATION: 22 June 1998 (June 22, 1998)

PUBLISHED IN: CTMB 45 page 676

EXPIRATION DATE: 10 October 2007 (October 10, 2007)

DURATION: 10 YEARS

LAST REPORTED OWNER(S): PHARMALIFE ITALIA S.r.l., Via F.lli Kennedy -  
Zona Industriale, Airuno (Lecco), IT (ITALY)  
AGENT: JACOBACCI & PARTNERS S.P.A., Via Senato, 8, Milano (MI)  
HISTORICAL INFORMATION:  
PUBLICATION OF APPLICATION:  
CTMB Volume 45 page 676 dated 22 June 1998

4/9/2 (Item 1 from file: 658)  
DIALOG(R) File 658: TRADEMARKSCAN(R) - Benelux  
(c) 2001 Compu-Mark N.V. All rts. reserv.

00336449

GASTRIN

INTL CLASS: 5 (Pharmaceuticals)  
STATUS: Registered  
GOODS/SERVICES: KL 5 HOMEOPATISCHE GENEESMIDDELEN.  
APPLICATION NUMBER: 787667  
REGISTRATION NUMBER: 517697  
APPLICATION DATE: 16 October 1992 (October 16, 1992)  
LAST FULL PUBLICATION: 01 February 1993 (February 1, 1993)  
PUBLISHED IN: BM 02 page 629  
EXPIRATION DATE: 16 October 2002 (October 16, 2002)  
DURATION: 10 YEARS  
LAST REPORTED OWNER(S): PFLUGER BV, Remmingweg 2, 1332 BE Almere,  
NL (NETHERLANDS)

4/9/3 (Item 1 from file: 669)  
DIALOG(R) File 669: TRADEMARKSCAN(R) - Japan  
(c) 2001 Thomson & Thomson. All rts. reserv.

01904284 \* TRADEMARK IMAGE AVAILABLE \*

GASTRIN

JAPANESE PRONUNCIATION: GASUTORIN  
CHARACTER TYPES: Katakana  
INTL CLASS: 5 (Pharmaceuticals)  
NATIONAL CLASS:  
01B01 (Pharmaceutical preparations)  
STATUS: Lapsed [Expired]  
APPLICATION NUMBER: H07-129953  
DATE FILED: December 18, 1995  
FINAL DISPOSITION: Decision of Refusal  
DURATION: 10 YEARS  
LAW IN EFFECT: 1991 Trademark Law  
LAST REPORTED OWNER(S):  
AGRO KANESHO K.K., MINATO, TOKYO, JP (JAPAN)  
HISTORICAL INFORMATION:  
Refusal Date: November 28, 1997  
COUNTRY OF FILING: JAPAN

4/9/4 (Item 2 from file: 669)  
DIALOG(R) File 669: TRADEMARKSCAN(R) - Japan  
(c) 2001 Thomson & Thomson. All rts. reserv.

00299888 \* TRADEMARK IMAGE AVAILABLE \*

GASTRIN RIAKIT

JAPANESE PRONUNCIATION: GASUTORINRIAKITTO  
CHARACTER TYPES: Katakana

INTL CLASS: 1 (Chemicals)  
 5 (Pharmaceuticals)  
 NATIONAL CLASS:  
 01B01  
 STATUS: Registered  
 APPLICATION NUMBER: S56-026636  
 REGISTRATION NUMBER: 1801587  
 REGISTERED: August 29, 1985  
 RENEWED: August 30, 1995  
 DATE FILED: April 06, 1981  
 LAST FULL PUBLICATION: July 11, 1983  
 DATE WILL EXPIRE: August 29, 2005  
 DURATION: 10 YEARS  
 LAW IN EFFECT: 1959 Trademark Law  
 LAST REPORTED OWNER(S):  
 DYNABOT K.K., MINATO, TOKYO, JP(JAPAN)  
 HISTORICAL INFORMATION:  
 Renewal Registration Date: August 30, 1995  
 Renewal Application number: H07-712752  
 Date Published: July 11, 1983  
 COUNTRY OF FILING: JAPAN

4/9/5 (Item 1 from file: 672)  
 DIALOG(R)File 672:TRADEMARKSCAN(R)-Germany  
 (c) 2001 Compu-Mark N.V. All rts. reserv.

00334156

NEY GASTRIN

INTL CLASS: 5 (Pharmazeutische erzeugnisse/Pharmaceuticals)  
 STATUS: Eintragung (Registered)  
 GOODS/SERVICES: ARZNEIMITTEL, NAEMLICH MAGEN-DARM-MITTEL.  
 APPLICATION NUMBER: V 18070  
 REGISTRATION NUMBER: 1062157  
 REGISTERED: 12 April 1984 (April 12, 1984)  
 APPLICATION DATE: 28 Juli 1982 (July 28, 1982)  
 LAST FULL PUBLICATION: 30 Mai 1984 (May 30, 1984)  
 PUBLISHED IN: WZBL II 10 page 1644  
 EXPIRATION DATE: 28 Juli 2002 (July 28, 2002)  
 DURATION: 10 YEARS  
 LAST REPORTED OWNER(S): vitOrgan Arzneimittel GmbH, 7302  
 Ostfildern-Ruit, Brunnwiesenstr. 21, DE (BUNDESREPUBLIK  
 DEUTSCHLAND / FEDERAL REPUBLIC OF GERMANY)  
 HISTORICAL INFORMATION:  
 BEKANNTMACHUNG (PUBLICATION OF APPLICATION):  
 WZBL I Volume 18 page 2943 dated 30 September 1982  
 VEROEFFENTLICHUNG DER EINTRAGUNG (PUBLICATION OF REGISTRATION):  
 WZBL II Volume 10 page 1644 dated 30 May 1984  
 VERLAENGERUNG (RENEWAL):  
 WZBL II Volume 20 page 4900 dated 31 October 1992

? ds

Set	Items	Description
S1	0	FLUO()GRP
S2	0	FLU? ? AND GRP
S3	0	GASTRIN ()RELEASING ()PEPTIDE?
S4	5	GASTRIN
S5	189	FLUO
S6	0	S5 AND PEPTIDE?

Delacroix 09/351,057

S7	0	S5 AND RELEAS?
S8	0	S5 AND GASTR?
S9	0	FLUS AND GRP
S10	87	GRP
S11	0	S10 AND GASTRIN?
S12	0	S10 AND FLU?
S13	0	S10 AND PEPTIDE?

? 411 - dialindex

Delacroix 09/351,057

You have 572 files in your file list.

(To see banners, use SHOW FILES command)

? s fluo and grp

Your SELECT statement is:

s fluo and grp

Items	File
-----	-----
Examined 50 files	
Examined 100 files	
Examined 150 files	
Examined 200 files	
7	349: PCT FULLTEXT_1983-2001/UB=20011122,UT=20011115
Examined 250 files	
1	351: Derwent WPI_1963-2001/UD,UM &UP=200169
1	399: CA SEARCH(R)_1967-2001/UD=13522
Examined 300 files	
Examined 350 files	
Examined 400 files	
2	590: KOMPASS Western Europe_2001/Sep
Examined 450 files	
Examined 500 files	
Examined 550 files	

4 files have one or more items; file list includes 572 files.



? b 349 351 399 590

29nov01 12:11:08 User035515 Session D460.2  
 \$0.00 0.065 DialUnits File410  
 \$0.00 Estimated cost File410  
 \$0.07 TELNET  
 \$0.07 Estimated cost this search  
 \$0.33 Estimated total session cost 0.139 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 349:PCT FULLTEXT 1983-2001/UB=20011122,UT=20011115

(c) 2001 WIPO/Univentio

\*File 349: Additional fulltext records and images will be added shortly. Additional coverage added. See HELP NEWS 349.

File 351:Derwent WPI 1963-2001/UD,UM &UP=200169

(c) 2001 Derwent Info Ltd

\*File 351: Price changes as of 1/1/01. Please see HELP RATES 351.

72 Updates in 2001. Please see HELP NEWS 351 for details.

File 399:CA SEARCH(R) 1967-2001/UD=13522

(c) 2001 AMERICAN CHEMICAL SOCIETY

\*File 399: Use is subject to the terms of your user/customer agreement.

RANK charge added; see HELP RATES 399.

File 590:KOMPASS Western Europe 2001/Sep

(c) 2001 KOMPASS Intl.

Set	Items	Description
---	-----	-----

? s fluo and grp

3272 FLUO

9927 GRP

S1 11 FLUO AND GRP

? rd s1

>>>Duplicate detection is not supported for File 349.

>>>Duplicate detection is not supported for File 351.

>>>Records from unsupported files will be retained in the RD set.

>>>Record 590:836464 ignored; incomplete bibliographic data, not retained - in RD set

>>>Record 590:741567 ignored; incomplete bibliographic data, not retained - in RD set

...completed examining records

S2 9 RD S1 (unique items)

? t 2/5/all

2/5/1 (Item 1 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2001 WIPO/Univentio. All rts. reserv.

00836404

USES OF BOMBESIN RECEPTOR 3

UTILISATIONS RECEPTEUR DE LA BOMBESINE DU TYPE 3

Patent Applicant/Assignee:

SMITHKLINE BEECHAM P L C, New Horizons Court, Brentford, Middlesex TW8 9EP, GB, GB (Residence), GB (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

SMART Darren, GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW, GB, GB (Residence), GB (Nationality), (Designated only for: US)

STRIJBOS Paul, GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW, GB, GB (Residence), NL (Nationality), (Designated only for: US)

Legal Representative:

CONNELL Anthony Christopher (agent), Corporate Intellectual Property,

GlaxoSmithKline, Two New Horizons Court, Brentford, Middlesex TW8 9EP,  
GB,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200168120 A2 20010920 (WO 0168120)

Application: WO 2001EP2812 20010313 (PCT/WO EP0102812)

Priority Application: GB 20006289 20000315

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU

CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR

KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE

SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: A61K-038/10

International Patent Class: A61K-038/17; G01N-033/68; A61P-009/10;

A61P-025/28

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 9711

English Abstract

The invention relates to newly identified uses of bombesin receptor subtype 3 (BRS3) BRS3 polypeptides and polynucleotides encoding such polypeptides, to their use in therapy of ischemia, of neurodegenerative diseases, of memory and attention disorders, and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

French Abstract

L'invention concerne des utilisations nouvellement identifiées des polypeptides formant le sous-type 3 du récepteur de la bombésine (BRS3) et des polynucleotides codant pour ces polypeptides, leur utilisation pour le traitement des ischémies, des maladies neurodégénératives, et pour l'identification de composés agonistes, antagonistes et/ou inhibiteurs présentant une utilité thérapeutique potentielle, ainsi que la production de ces polypeptides et polynucleotides.

Legal Status (Type, Date, Text)

Publication 20010920 A2 Without international search report and to be republished upon receipt of that report.

2/5/2 (Item 2 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2001 WIPO/Univentio. All rts. reserv.

00744477

48 HUMAN SECRETED PROTEINS

48 PROTEINES HUMAINES SECRETEES

Patent Applicant/Assignee:

HUMAN GENOME SCIENCES INC, 9410 Key West Avenue, Rockville, MD 20850, US,  
US (Residence), US (Nationality), (For all designated states except:  
US)

Patent Applicant/Inventor:

ROSEN Graig A, 22400 Rolling Hill Road, Laytonsville, MD 20882, US, US  
(Residence), US (Nationality), (Designated only for: US)

RUBEN Steven M, 18528 Heritage Hills Drive, Laytonsville, MD 20882, US,  
US (Residence), US (Nationality), (Designated only for: US)

Delacroix 09/351,057

KOMATSOULIS George, 9518 Garwood Street, Silver Spring, MD 20901, US, US  
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

HOOVER Kenley K, Human Genome Sciences, Inc., 9410 Key West Avenue,  
Rockville, MD 20850, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200056754 A1 20000928 (WO 0056754)

Application: WO 2000US6792 20000316 (PCT/WO US0006792)

Priority Application: US 99125362 19990319; US 99169980 19991210

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK  
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR  
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ  
TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: C07H-021/04

International Patent Class: C07K-014/00; C07K-016/00; C12N-015/00;  
C12N-015/63; C12N-015/85; C12N-015/86; C12Q-001/68; G01N-033/53

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 140200

English Abstract

The present invention relates to 48 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

French Abstract

L'invention porte sur de nouvelles proteines humaines secretees et sur des acides nucleiques isoles comportant les regions codantes des genes codant pour lesdites proteines. L'invention porte egalement sur des vecteurs, cellules hotes, anticorps, et methodes de recombinaison servant a produire lesdites proteines humaines secretees; elle porte en outre sur des procedes diagnostiques et therapeutiques permettant de diagnostiquer et traiter les affections liees auxdites nouvelles proteines humaines secretees.

Legal Status (Type, Date, Text)

Publication 20000928 A1 With international search report.

Publication 20000928 A1 Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

Examination 20010111 Request for preliminary examination prior to end of 19th month from priority date

2/5/3 (Item 3 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2001 WIPO/Univentio. All rts. reserv.

00504143

IDENTIFICATION OF SUBSTANCES THAT MODIFY CELLULAR SECRETORY FUNCTION  
LIGNEES CELLULAIRES RECOMBINEES POUR LE CRIBLAGE DE MEDICAMENTS

Patent Applicant/Assignee:

BETAGENE INC,  
THIGPEN Anice E,  
QUAADE Christian,  
CLARK Samuel A,

Inventor(s):

THIGPEN Anice E,  
QUAADE Christian,  
CLARK Samuel A,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9935495 A2 19990715

Application: WO 99US551 19990111 (PCT/WO US9900551)

Priority Application: US 9871193 19980112; US 9871209 19980112; US  
9872556 19980112; US 9887821 19980603; US 9887848 19980603

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES

FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV

MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG

US US US US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD

RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

CG CI CM GA GN GW ML MR NE SN TD TG

Main International Patent Class: G01N-033/50

International Patent Class: C12N-005/10; G01N-033/74

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 82463

English Abstract

The present invention provides methods of screening for modulators of secretory function. In particular, the present invention describes immortalized neuroendocrine secretory cells to screen for novel substances that may be used to regulate secretory function i(in vitro) and i(in vivo).

French Abstract

La presente invention concerne des methodes de criblage pour la detection de modulateurs de fonction secretoires. En particulier, l'invention decrit des cellules secretoires neuro-endocriniennes immortalisees permettant de cribler de nouvelles substances pouvant s'utiliser pour reguler la fonction secretoire i(in vitro) et i(in vivo).

2/5/4 (Item 4 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2001 WIPO/Univentio. All rts. reserv.

00503903

COMPOSITIONS AND METHODS FOR REGULATED SECRETION FROM NEUROENDOCRINE CELL  
LINES

COMPOSITIONS ET PROCEDES REGULANT LA SECRETION DE LIGNEES DE CELLULES  
NEUROENDOCRINES

Patent Applicant/Assignee:

BETAGENE INC,  
CLARK Samuel A,  
THIGPEN Anice E,

Inventor(s):

CLARK Samuel A,  
THIGPEN Anice E,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9935255 A2 19990715

Application: WO 99US631 19990111 (PCT/WO US9900631)

Priority Application: US 9871193 19980112; US 9871209 19980112; US  
9872556 19980112; US 9887821 19980603; US 9887848 19980603

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES  
FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV  
MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG  
US US US US US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD  
RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF  
CG CI CM GA GN GW ML MR NE SN TD TG

Main International Patent Class: C12N-015/10

International Patent Class: A61K-048/00; A61K-038/28; C12N-015/85

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 80426

#### English Abstract

The present invention provides compositions and methods of comprising engineered human neuroendocrine cell lines having a regulated secretory pathway. More particularly, the present invention provides methods and compositions for engineering regulated secretion into cells. Certain aspects of the invention provide glycemic sensing mechanisms to a population of genetically engineered cells. In particular embodiments, the present invention provides compositions and methods of providing indirect glycemic sensing mechanisms to a population of genetically engineered cells. Specifically contemplated are methods and compositions for engineering indirect glucose sensing and glucose counter regulation capacity into cells. Methods of using these cells for minimizing hypoglycemia in diabetic therapy are also disclosed.

#### French Abstract

L'invention porte sur des compositions et procedes relatifs a des lignees de cellules neuroendocrines humaines obtenues par genie genetique, a mecanisme secretoire regule, et plus particulierement sur des procedes et compositions assurant par genie genetique la regulation de la secretion de cellules. Certains aspects de l'invention ont trait a des mecanismes de detection glycémique induits par genie genetique dans une population de cellules. Dans des executions particulieres, l'invention porte sur des compositions et procedes conferant a une population de cellules obtenues par genie genetique des mecanismes indirects de detection glycémique. L'invention porte specifiquement sur des procedes et compositions d'induction par genie genetique dans des cellules de la capacite de detection indirecte du glucose et d'une capacite de contre regulation du glucose, et sur des procedes d'utilisation desdites cellules pour reduire l'hypoglycémie dans le traitement du diabete.

2/5/5 (Item 5 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2001 WIPO/Univentio. All rts. reserv.

00503890

MEDIA FOR NEUROENDOCRINE CELLS

MILIEU DE CULTURE DE CELLULES NEUROENDOCRINES

Patent Applicant/Assignee:

BETAGENE INC,

CLARK Samuel A,

QUAADE Christian,

Inventor(s):

CLARK Samuel A,

QUAADE Christian,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9935242 A1 19990715

Application: WO 99US633 19990111 (PCT/WO US9900633)

Priority Application: US 9871193 19980112; US 9871209 19980112; US 9872556 19980112; US 9887821 19980603; US 9887848 19980603

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

Main International Patent Class: C12N-005/00

International Patent Class: A01N-001/02

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 78820

#### English Abstract

The present invention is directed to providing media compositions and culturing conditions for the growth and function of secretory cells. More particularly, the present invention provides a media to be used for establishing, maintaining, and propagating neuroendocrine cells in both bench and bulk production scale culture, with and without serum.

#### French Abstract

L'invention porte sur des compositions de milieux et des conditions de culture favorisant la croissance et la fonction de cellules sécrétrices, et en particulier sur un milieu développant, conservant et propageant les cellules neuroendocrines, utilisable pour des cultures à petite ou grande échelle, avec ou sans sérum.

2/5/6 (Item 6 from file: 349)

DIALOG(R) File 349: PCT FULLTEXT

(c) 2001 WIPO/Univentio. All rts. reserv.

00306275

A NOVEL EXPRESSION-CLONING METHOD FOR IDENTIFYING TARGET PROTEINS FOR EUKARYOTIC TYROSINE KINASES AND NOVEL TARGET PROTEINS

NOUVEAU PROCÉDÉ D'EXPRESSION-CLONAGE UTILISÉ POUR IDENTIFIER DES PROTÉINES

A CIBLES DES TIROSINE-KINASES EUKARYOTES, ET NOUVELLES PROTÉINES CIBLES

Patent Applicant/Assignee:

NEW YORK UNIVERSITY,

Inventor(s):

SCHLESSINGER Joseph,

SKOLNIK Edward Y,

MARGOLIS Benjamin L,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9524426 A1 19950914

Application: WO 95US3385 19950313 (PCT/WO US9503385)

Priority Application: US 94887 19940311

Designated States: AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KR KZ LK

LR LT LV MD MG MN MW MX NO NZ PL RO RU SD SG SI SK TJ TT UA UZ VN KE MW

SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

CM GA GN ML MR NE SN TD TG

Main International Patent Class: C07K-014/47

International Patent Class: C07K-16:40; C12N-15:12

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 33591

#### English Abstract

A novel expression cloning method is provided for the detection, identification and purification of target proteins capable of binding at least to a tyrosine-phosphorylated domain of a eukaryotic tyrosine kinase using novel peptide probes comprising an amino acid sequence substantially corresponding to a portion of a tyrosine-phosphorylated domain of a tyrosine kinase. The probe has at least one phosphorylated tyrosine residue and may be detectably labeled. Also disclosed is a method for preparing the probe, a method for mapping to a chromosome a gene encoding a protein capable of binding to tyrosine-phosphorylated domains of tyrosine kinases, and a method for purifying such a protein with the probe. Non-limiting examples of novel proteins discovered using the above cloning method include GRB-1, GRB-2, GRB-3, GRB-4 and GRB-7, as well as nucleic acid encoding these proteins, and methods for detecting these proteins are also provided.

## French Abstract

Un nouveau procede d'expression-clonage est utilise dans la detection, l'identification et la purification de proteines cibles pouvant se lier au moins a un domaine phosphoryle par tyrosine d'une tyrosine-kinase eukaryote a l'aide de nouvelles sondes peptidiques comprenant une sequence d'acides amines correspondant essentiellement a une partie du domaine phosphoryle par tyrosine d'une tyrosine-kinase. La sonde possede au moins un reste de tyrosine phosphoryle et peut etre marquee de maniere detectable. L'invention se rapporte egalement a un procede de preparation de la sonde, a un procede de cartographie, sur un chromosome, d'un gene codant une proteine pouvant se lier a des domaines phosphoryles par tyrosine des tyrosine-kinases, et a un procede de purification de cette proteine a l'aide de la sonde. L'invention se rapporte encore a des exemples non limitatifs des nouvelles proteines decouvertes a l'aide du procede de clonage susmentionne et qui comprennent GRB-1, GRB-2, GRB-3, GRB-4 et GRB-7, ainsi qu'a l'acide nucleique codant ces proteines, et au procede de detection de ces proteines.

2/5/7 (Item 7 from file: 349)  
 DIALOG(R)File 349:PCT FULLTEXT  
 (c) 2001 WIPO/Univentio. All rts. reserv.

00246571

BIOMATERIALS FOR BONE REPLACEMENTS  
 BIOMATERIAUX UTILISES POUR REMPLACER DES OS

Patent Applicant/Assignee:

FIDIA S P A,  
 DORIGATTI Franco,  
 CALLEGARO Lanfranco,  
 ROMEO Aurelio,

Inventor(s):

DORIGATTI Franco,  
 CALLEGARO Lanfranco,  
 ROMEO Aurelio,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9320858 A1 19931028  
 Application: WO 93EP933 19930416 (PCT/WO EP9300933)  
 Priority Application: IT 92PD72 19920417

Designated States: AU BB BG BR CA CZ FI HU JP KP KR LK MG MN MW NO NZ PL RO  
 RU SD SK UA US VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ  
 CF CG CI CM GA GN ML MR NE SN TD TG

Main International Patent Class: A61L-027/00

Publication Language: English

Fulltext Availability:

Detailed Description  
 Claims

Fulltext Word Count: 13491

English Abstract

Bonding solutions for granular bone replacements are provided, comprising hyaluronic acid or hyaluronic acid derivatives such as hyaluronic acid esters and hyaluronic acid antibiotic salts in combination with natural or artificial bone granules. These solutions can be used in human and veterinary dentistry and bone surgery as granular bone replacements to promote the growth and repair of damaged or defective bone tissue.

French Abstract

Solutions permettant de fixer des produits de remplacement d'os granulaires comprenant de l'acide hyaluronique ou des derives d'acide hyaluronique tels que des esters d'acide hyaluronique et des sels d'acide hyaluronique ainsi qu'un antibiotique combines a des granules d'os naturel ou artificiel. On peut utiliser ces solutions en dentisterie humaine et veterinaire et en chirurgie osseuse comme produits de remplacement d'os granulaires, pour stimuler la croissance et la reparation de tissus osseux endommages ou defectueux.

2/5/8 (Item 1 from file: 351)  
DIALOG(R)File 351:Derwent WPI  
(c) 2001 Derwent Info Ltd. All rts. reserv.

000554293

WPI Acc No: 1967-07063G/196801

Related WPI Acc No: 1966-08701F

O-acylates of actinospectacin and dihydro-actinospectacin

Patent Assignee: UPJOHN CO (UPJO )

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
CA 743971	A					196801 B

Priority Applications (No Type Date): US 62167930 A 19620122; US 62167930 A 19620122

Abstract (Basic): CA 743971 A

Compounds

R= acyl **grp.** of 2-12C atoms (opt. substd, by halogen, NO<sub>2</sub>, NH<sub>2</sub>, OH, CN, CNS or lower alkoxy) or lower alkoxycarbonyl.

The acyl groups. may be aliphatic, cyclo-aliphatic aromatic or aromatic-aliphatic.

With amine **fluosilicates** and condensed with formaldehyde and amine thiocyanates, as miticide.

9-O-acetyl-actinospectacin (I, R=OC.CH<sub>3</sub>)

Title Terms: ACTINOSPECTACIN; ACTINOSPECTACIN

Derwent Class: C00

File Segment: CPI

2/5/9 (Item 1 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

89036841 CA: 89(5)36841b CONFERENCE PROCEEDING

Experimental and clinical studies with

2,2'-anhydro-1-.beta.-D-arabinofuranosyl-5-fluorocytosine

AUTHOR(S): Burchenal, Joseph H.; Kalaher, Kathleen; Clarkson, Bayard; Kememey, Nancy; Young, Charles; Fox, Jack; Krakoff, Irwin

LOCATION: Mem. Sloan-Kettering Cancer Cent., New York, N. Y.

JOURNAL: Curr. Chemother., Proc. Int. Congr. Chemother., 10th EDITOR: Siegenthaler, Walter (Ed), Luethy, Ruedi (Ed), DATE: 1978 VOLUME: 2,



PAGES: 1206-8 CODEN: 37XLA2 LANGUAGE: English MEETING DATE: 77  
PUBLISHER: Am. Soc. Microbiol., Washington, D. C  
SECTION:

CA001006 Pharmacodynamics

IDENTIFIERS: arabinofuranosyl fluorocytosine deriv antitumor,  
flourocytosine deriv antitumor

CAS REGISTRY NUMBERS:

37717-21-8 antitumor activity of

154-42-7 antitumor activity of arabinofuranosylfluorocytosine deriv. and

GRP: 1

? t 2/kwic/allk

```
>>>'ALLK' not recognized as item list
```

? t 2/kwic/all

```
>>>KWIC option is not available in file(s): 399
```

2/KWIC/1 (Item 1 from file: 349)

DIALOG(R) File 349: (c) 2001 WIPO/Univentio. All rts. reserv.

Fulltext Availability:

Detailed Description

### Detailed Description

... The mammalian counterparts of the frog peptide are neuromedin B (NMB) and gastrin-releasing peptide (GRP), I 0 as well as the biologically active GRP fragment neuromedin C (NMC); (Kroog et al (I 995) Med.

Res. Rev. 15, 3 89...

...originally defined in terms of the rank order of potency of the endogenous ligands NMB, GRP and bombesin, with the rank order of potency being NMB>bombesin>GR.P at the BB I receptor and GRP >bombesin>NMB at the BB2 receptor (Kroog et al (1995) supra). Further characterisation became possible with the development of a range of peptide GRP antagonists, most notably BW 1023U90 and (D-Phe6 DesMet14) bombesin 6-14 ethylamide, although its natural ligand has yet to be identified, with all known natural bombesin-like peptides, including GRP, NMB and NMC, having very low (high @LM) affinity. However, some GRP antagonists have moderate (low @LM) affinity at ...foetal calf serum and 1% L-glutamine; and then loaded with the cytoplasmic calcium indicator Fluo-3AM (4gM) in the presence of 2.5mM probenecid at 37°C for 60 min. The...

...12 full

Bombesin <5 23% at I OptM

PG-L 5.54+/-0.05 full

GRP <5 23% at 10gM

13

[D-Ty<sup>?</sup>, PAla<sup>?</sup>, Phe 8.02+/-0.03 fall

Me...

2/KWIC/2 (Item 2 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

Fulltext Availability:

Detailed Description

### Detailed Description

```
... Identities = 21/68 (30%), Positives = 27/68 (39%), Frame = -1
```

O: 615 GRPOGGDDLPGVLGQPTYHQQPDREGWAGP --- PAAETMPQAACQLLLPAEPDIGLVLP 445

GRP G PG +G P P G+ G P P C + P + VP

S: 79 GRP-GPPGFPGPMGPPGPPGPPGPPGYPGEGGMPGQPAPPPPPCPPICPTQ -----

CVP 131  
Q: 444 GCKQRQCPAQR 412  
C Q CP ++  
S: 132 YCPQYCCPLKK 142  
The...

2/KWIC/3 (Item 3 from file: 349)  
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

Fulltext Availability:  
Detailed Description

Detailed Description

... are not able to synthesize the peptide neuromedin B (NMB) or the gastrin releasing peptide (GRP).

Other lung carcinoma cells include cells designated herein as PG H04, PG H05, PG H07...

...the peptide NMB at 0.1 pmol/mg protein, but not the gastrin releasing peptide (GRP).

Another lung carcinoma cell that may prove a useful host cell in the context...the peptide NMB (at 0.1 pmol/mg protein), but not the gastrin releasing peptide (GRP). The cell line secretes a parathyroid hormone-like protein which is calcium stimulated through a...

...are not able to synthesize the peptide neuromedin B (NMB) or the gastrin-releasing peptide (GRP). They express easily detectable levels of p53 mRNA compared to levels found in normal lung... Calciumbinding dyes that increase in intensity of fluorescence in a dose-dependent fashion, such as Fluo-3 and Calcium green, are widely used in cell-based assays in the pharmaceutical industry...

2/KWIC/4 (Item 4 from file: 349)  
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

Fulltext Availability:  
Detailed Description

Detailed Description

... are not able to synthesize the peptide neuromedin B (NMB) or the gastrin releasing peptide (GRP).

Other lung carcinoma cells include cells designated herein as PG H04, PG H05, PG H07...the peptide NMB at 0.1 pmol/mg protein, but not the gastrin releasing peptide (GRP).

Another lung carcinoma cell that may prove a useful host cell in the context of...

...the peptide NMB (at 0.1 pmol/mg protein), but not the gastrin releasing peptide (GRP). The cell line secretes a parathyroid hormone-like protein which is calcium stimulated through a...

...are not able to synthesize the peptide neuromedin  
59

(NMTS) or the gastrin-releasing peptide (GRP). They express easily detectable levels of p53 mRNA compared to levels found in normal lung... binding dyes that increase in intensity of fluorescence in a dose-dependent fashion, such as Fluo-3 and Calcium green, are

widely used in cell-based assays in the pharmaceutical industry...

2/KWIC/5 (Item 5 from file: 349)  
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

Fulltext Availability:  
Detailed Description

Detailed Description

... are not able to synthesize the peptide neuromedin B (NMB) or the gastrin releasing peptide (GRP).

Other lung carcinoma cells include cells designated herein as PG H04, PG H05, PG H079...the peptide NMB at 0.1 pmol/mg protein, but not the gastrin releasing peptide (GRP).

Another lung carcinoma cell that may prove a useful host cell in the context of...

...the peptide NMB (at 0.1 pmol/mg protein), but not the gastrin releasing peptide (GRP). The cell line secretes a parathyroid hormone-like protein which is calcium stimulated through a...

...are not able to synthesize the peptide neuromedin B (NMB) or the gastrin-releasing peptide (GRP). They express easily detectable levels of p53 mRNA compared to levels found in normal lung...binding dyes that increase in intensity of fluorescence in a dose-dependent fashion, such as **Fluo**-3 and Calcium green, are widely used in cell-based assays in the pharmaceutical industry...

2/KWIC/6 (Item 6 from file: 349)  
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

Fulltext Availability:  
Detailed Description

Detailed Description

... fluorescent labelling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine. Suitable **fluo**-rescent probes are well known or commercially available, such as from Molecular Probes, Inc., Eugene Oregon.

The peptide probe or anti-target protein antibody can also be detectably labeled using **fluo** rescence emitting metals such as <sup>151</sup>Eu, or others of the lanthanide series. These metals...eukaryotic tyrosine kinases, which include, as non-limiting examples, GRB proteins such as GRB-1, **GRP**-2, GRB-3, GRB-4, GRB-7 or GRB-10 proteins are included. In another...

2/KWIC/7 (Item 7 from file: 349)  
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

Fulltext Availability:  
Detailed Description

Detailed Description

... as ephedrine,

isoDroteranolr epinephrine; phenothiazine drugs such as  
'he pipothiazine, carphenaz ne, homofenazins,  
perphenazi  
acetophenazine, **fluophenazine**, and N@  
hydr azins chloride; thioxanthene drugs  
such as flupenthixol and clopenthixol; anticonvulsants  
such as...ethyl ester.-Of  
hyaluronic acid (HY) @ 75\* of esteXified carboxylic  
aroups @ 251 of salified carboXylic **grp**  
.=s (Nal  
12A g of HY tetrabutylammonium salt with a  
molecular weight of 250,000...

2/KWIC/8 (Item 1 from file: 351)  
DIALOG(R)File 351:(c) 2001 Derwent Info Ltd. All rts. reserv.

...Abstract (Basic): R= acyl **grp.** of 2-12C atoms (opt. substd, by  
halogen, NO2, NH2, OH, CN, CNS or lower...

...With amine **fluosilicates** and condensed with formaldehyde and amine  
thiocyanates, as miticide...